Buy CMMB by Nov 20, 2026.

Quarterly filings was published on August 19th and with that they finally wrote about CVRs, milestone payments shareholders can get **Chemomab shareholders** will receive contingent value rights (CVRs), providing the opportunity to **receive future payments of $10 million upon FDA approval of nebokitug for any indication** and **$40 million if Chemomab’s PSC program advances to a Phase 3 clinical trial** or if there is a disposition of nebokitug in the indication of PSC which may be settled in cash, stock …